Call for papers: Connective tissue disease-associated interstitial lung disease
Published in Healthcare & Nursing and General & Internal Medicine
BMC Pulmonary Medicine is calling for submissions to our Collection on connective tissue disease-associated interstitial lung disease.
Interstitial Lung Disease (ILD) is a common manifestation of several systemic autoimmune connective tissue diseases (CTDs). While ILD can manifest with all CTDs, it most commonly affects individuals with rheumatoid arthritis (RA, 10-30%), systemic sclerosis (SSc, 40-80%), and idiopathic inflammatory myopathy (IIM, 40%). In some patients, ILD could also be the initial or only manifestation of an underlying CTD and the research classification “interstitial pneumonia with autoimmune features (IPAF)” was recently proposed to identify these patients. ILD poses a significant burden, contributing to morbidity and mortality among CTD patients. Given the complexity in the diagnosis and treatment of CTD-related ILD, a multidisciplinary approach to management is crucial.
Over the years, advances in research have improved our understanding and management of CTD-related ILD. However, there are still significant gaps in our knowledge. With the emergence of new therapies for this patient population, there is an increased need to identify clinical characteristics and biomarkers that could predict those who are likely to develop ILD and/or have progressive disease. There is also a continued need to understand additional mechanistic pathways that lead to ILD, in order to develop novel therapies.
For this research topic collection, BMC Pulmonary Medicine invites basic and clinical research papers that could enhance our understanding of CTD-associated ILD and contribute to the advancement of patient care.
Topics of interest for this Collection include but are not limited to:
• Mechanisms and genetics associated with CTD-ILD
• Epidemiology of CTD-ILD: prevalence, mortality, hospitalizations
• Early diagnosis, risk predictors and biomarkers that could predict development and prognosis of CTD-ILD
• Novel therapies for CTD-ILD
• Barriers/limitations to timely care
• Multidisciplinary approach to diagnosis and treatment, and other treatment models
Meet the Guest Editors
Bruno Guedes Baldi: University of Sao Paulo Medical School, Brazil
Dr Bruno Guedes Baldi is a Pulmonologist. He is the Medical Assistant of the Pulmonary Division, Heart Institute (InCor) at the University of Sao Paulo Medical School, Sao Paulo, Brazil. His expertise is in interstitial and rare lung diseases, with a hundred articles published. He has served as an editor, including Associate Editor of Frontiers in Medicine and BMC Pulmonary Medicine, as well as Editor-in-Chief of the Jornal Brasileiro de Pneumologia from 2019 to 2022
Niranjan Jeganathan: Loma Linda University Health System School of Medicine, US
Dr Niranjan Jeganathan is a pulmonologist with a special interest in interstitial lung diseases (ILD). He is the Director of the ILD Center at Loma Linda University (California) which is a Pulmonary Fibrosis Foundation Care Center. His research interest within ILD is in understanding the epidemiology of ILD including Connective Tissue Diseases-Related ILD. He has been an editor for other research collections related to ILD. In addition, he has reviewed numerous ILD articles for many different journals.
Jin Woo Song: University of Ulsan College of Medicine, South Korea
Dr Jin Woo Song is Professor in the Department of Pulmonary and Critical Care Medicine at the University of Ulsan College of Medicine, South Korea. He is currently Director of the ILD Program at Asan Medical Center in Seoul, South Korea. His academic interests include the effects of air pollution on clinical outcomes in ILD, metabolic changes in ILD and biomarkers in ILD.
Submission Guidelines
This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Connective tissue disease-associated interstitial lung disease" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.
Submission Status: Open | Submission Deadline: 8 April 2024
Follow the Topic
-
BMC Pulmonary Medicine
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Technological advancements in diagnosis of pulmonary disease
BMC Pulmonary Medicine is calling for submissions to our Collection on technological advancements in the diagnosis of pulmonary disease.
The landscape of interventional pulmonary medicine is evolving rapidly, propelled by innovative technologies aimed at enhancing the minimally invasive diagnosis and treatment of lung diseases. Advances in medical technology, such as artificial intelligence, machine learning, and novel imaging techniques, are providing clinicians with unprecedented tools for diagnosing cancers and other diseases of the chest and mediastinum as well as chronic obstructive pulmonary disease (COPD) and asthma. This Collection seeks to explore the latest minimally invasive endoscopic diagnostic and therapeutic innovations that are reshaping our understanding of pulmonary diseases, thereby improving patient outcomes and fostering personalized treatment strategies.
Recent advancements, such as the development of novel disease biomarkers and enhanced diagnostic and therapeutic tools, have the potential to revolutionize clinical practices. This could lead to earlier interventions and better outcomes, and by integrating new methods and technologies, healthcare providers can improve early detection, diagnostic accuracy and efficiency, and therapies ultimately leading to better management of lung diseases and improved quality of life for patients.
Potential research topics can include but are not limited to:
- Diagnostic innovations in pulmonary disease
- New technologies in lung disease diagnosis
- Novel disease biomarkers for pulmonary conditions
- Advancements in diagnostic and disease monitoring techniques
- Horizon scanning for future diagnostic tools
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
This Collection supports research aligned with SDG 3: Good Health and Well-Being and SDG 9: Industry, Innovation and Infrastructure.
Publishing Model: Open Access
Deadline: May 21, 2027
Pediatric pulmonary disease and disorders
BMC Pulmonary Medicine is calling for submissions to our Collection on pediatric pulmonary diseases and disorders. Pediatric pulmonary diseases and disorders encompass a diverse range of conditions affecting the respiratory health of children, including asthma, cystic fibrosis, bronchitis, pulmonary vascular disease, ciliopathies, bronchopulmonary dysplasia, interstitial and diffuse lung diseases of childhood, and pulmonary infections including tuberculosis. These conditions can significantly impact a child's quality of life and overall development, making early diagnosis and effective management critical. The complexities of pediatric pulmonary disorders necessitate a multidisciplinary approach, bringing together pediatricians, pulmonologists, respiratory therapists, and researchers to develop better understanding and treatments.
Advances in the field have led to improved diagnostic techniques, targeted therapies, and a deeper understanding of the pathophysiological mechanisms underlying these conditions. With the rise of personalized medicine and innovative treatment options, the outlook for children suffering from pulmonary disorders continues to improve. Furthermore, research has highlighted the importance of addressing environmental factors, enhancing preventive measures, and fostering family-centered care in managing these conditions effectively.
Future research in pediatric pulmonary disorders may pave the way for groundbreaking treatments, including gene therapy and advanced biologics tailored to the individual needs of pediatric patients. Additionally, as our understanding of the interplay between genetics, environment, and respiratory health grows, we may see the development of novel prevention strategies that can significantly reduce the incidence and impact of these diseases in children.
Potential research topics can include but are not limited to:
- Asthma management in pediatric populations
- Advances in cystic fibrosis therapies
- Understanding bronchopulmonary dysplasia
- Pediatric pneumonia and primary ciliary dyskinesia: trends and treatments
- Pediatric interstitial lung disease
- Tuberculosis in children: challenges and strategies
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 09, 2027
